Cognitive impairment in depression: recent advances and novel treatments
Open accessThe DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Abstract
In the past, little or no attention was paid to cognitive disorders associated with depression (a condition sometimes termed pseudodementia). However, recent years have seen a growing interest in these changes, not only because of their high frequency in acute-stage depression, but also because they have been found to persist, as residual symptoms (in addition to affective and psychomotor ones), in many patients who respond well to antidepressant treatment. These cognitive symptoms seem to impact significantly not only on patients' functioning and quality of life, but also on the risk of recurrence of depression. Therefore, over the past decade, pharmacological research in this field has focused on the development of new agents able to counteract not only depressive symptoms, but also cognitive and functional ones. In this context, novel antidepressants with multimodal activity have emerged. This review considers the different issues, in terms of disease evolution, raised by the presence of cognitive disorders associated with depression and considers, particularly from the neurologist's perspective, the ways in which the clinical approach to cognitive symptoms, and their interpretation to diagnostic and therapeutic ends, have changed in recent years. Finally, after outlining the pharmacodynamics and pharmacokinetics of the first multimodal antidepressant, vortioxetine, it reports the main results obtained with the drug in depressed patients, also in consideration of the ever-increasing evidence on its different mechanisms of action in animal models.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Additionally, we used a multidimensional approach to evaluate trial outcomes; symptom assessments were complemented with evaluation of change in subjective mental health behaviors and quality of life, as well as change in objective measures of neuro-cognition that are impacted in depression [31–37].”
From Personalized machine learning guided intervention for optimizing lifestyle behaviors in depression: a pilot study (2026) · cites this paper as [35]
The cited source says what the claim attributes to it.
In the citing paper
“Notably, while depression can be associated with cognitive deficits [31–37]”
From Personalized machine learning guided intervention for optimizing lifestyle behaviors in depression: a pilot study (2026) · cites this paper as [35]
In the citing paper
“Furthermore, deficits in memory, attention and executive functioning have been observed in the absence of a current depressive episode28-31 and even in individuals responding well to antidepressant treatment for affective symptoms23, suggesting that cognitive deficits are only partly a state-dependent phenotype in MDD.”
From Dysregulation of adult hippocampal neuroplasticity in major depression: Pathogenesis and therapeutic implications (2022) · cites this paper as [31]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yaşlı Kadınlarda Üreme Sağlığı
Kokanalı, D., & Engin Üstün, Y. (n.d.) · DergiPark (Istanbul University) · Cited by 170,090
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Diagnostic and Statistical Manual of Mental Disorders
(2012) · SpringerReference · doi:10.1007/springerreference_121117 · Cited by 20,570
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70090-0 · Cited by 3,321
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (2011) · Neurology · doi:10.1212/01.wnl.0000400650.92875.cf · Cited by 1,495
Ownby, R. L., Crocco, E., Acevedo, A., John, V., & Loewenstein, D. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.5.530 · Cited by 1,493 · cited 1×
“In this regard, a more recent meta-analysis study found depression to be associated with a twofold increased risk of developing dementia.(16) Along the same lines, an observational study found that over a period of at least five years, more than 70% of elderly patients initially presenting with pseudodementia converte…”
BackgroundMillan, M. J., Agid, Y., Brüne, M., Bullmore, E. T., Carter, C. S., Clayton, N. S., Connor, R., Davis, S., Deakin, B., DeRubeis, R. J., et al. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3628 · Cited by 1,292
Neuropsychiatric Disease and Treatment
(2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt · Cited by 1,179
McIntyre, R. S., Cha, D. S., Soczynska, J. K., Woldeyohannes, H. O., Gallaugher, L. A., Kudlow, P., Alsuwaidan, M., & Baskaran, A. (2013) · Depression and Anxiety · doi:10.1002/da.22063 · Cited by 765
Bang-Andersen, B., Ruhland, T., Jørgensen, M., Smith, G., Frederiksen, K., Jensen, K. G., Zhong, H., Nielsen, S. M., Hogg, S., Mørk, A., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101459g · Cited by 606 · cited 1×
“Vortioxetine is an example of this latter category of molecules, termed “multimodal”: indeed, as well as inhibiting serotonin (5-HT) reuptake mediated by the serotonin reuptake transporter (SERT) protein, it also modulates the activity of other serotonin (5-HT) receptors.(34)”
BackgroundSanchez, C., Asin, K. E., & Artigas, F. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.07.001 · Cited by 547 · cited 1×
“Vortioxetine’s 5-HT3 receptor antagonism is also thought to inhibit the activity of GABAergic interneurons (per se inhibitors) on pyramidal neurons and thus to trigger increased release of glutamate by the latter.(45,46)”
BackgroundConradi, H. J., Ormel, J., & de Jonge, P. (2011) · Psychological Medicine · doi:10.1017/s0033291710001911 · Cited by 515
The course of geriatric depression with "reversible dementia": a controlled study
(1993) · American Journal of Psychiatry · doi:10.1176/ajp.150.11.1693 · Cited by 505
Screening for anxiety and depression: reassessing the utility of the Zung scales
Dunstan, D. A., Scott, N., & Todd, A. K. (2017) · BMC Psychiatry · doi:10.1186/s12888-017-1489-6 · Cited by 461
Katona, C., Hansen, T., & Olsen, C. K. (2012) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3283542457 · Cited by 445
McIntyre, R. S., Lophaven, S., & Olsen, C. K. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145714000546 · Cited by 433
Kiloh, L. G. (1961) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1961.tb07367.x · Cited by 363
Rovner, B. W. (1991) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1991.03460080063033 · Cited by 342
Rosenblat, J. D., Kakar, R., & McIntyre, R. S. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv082 · Cited by 315 · cited 1×
“Furthermore, it is the only antidepressant agent, among those to date evaluated, showing relatively strong evidence of a positive effect on multiple cognitive domains; for others (SSRIs, SNRIs and bupropione), on the other hand, the available evidence is still relatively weak.(67) Dovepress Perini et al”
BackgroundMahableshwarkar, A. R., Zajecka, J., Jacobson, W., Chen, Y., & Keefe, R. S. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.52 · Cited by 307
Castro-Costa, E., Dewey, M., Stewart, R., Banerjee, S., Huppert, F., Mendonca-Lima, C., Bula, C., Reisches, F., Wancata, J., Ritchie, K., et al. (2007) · British Journal of Psychiatry · doi:10.1192/bjp.bp.107.036772 · Cited by 260
Synaptic Mechanisms Underlying Rapid Antidepressant Action of Ketamine
Kavalali, E. T., & Monteggia, L. M. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.12040531 · Cited by 258
Varma, A. R., Snowden, J. S., Lloyd, J. J., Talbot, P. R., Mann, D. M. A., & Neary, D. (1999) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.2.184 · Cited by 238
Depression in Europe: Geographical distribution among older people
Copeland, J. R. M., Beekman, A. T. F., Dewey, M. E., Hooijer, C., Jordan, A., Lawlor, B. A., Lobo, A., Magnusson, H., Mann, A. H., Meller, I., et al. (1999) · British Journal of Psychiatry · doi:10.1192/bjp.174.4.312 · Cited by 236
Baldwin, D. S., Chrones, L., Florea, I., Nielsen, R., Nomikos, G. G., Palo, W., & Reines, E. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116628440 · Cited by 187
Pehrson, A. L., Cremers, T., Bétry, C., van der Hart, M. G. C., Jørgensen, L., Madsen, M., Haddjeri, N., Ebert, B., & Sanchez, C. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.04.006 · Cited by 155
McIntyre, R. S., Xiao, H. X., Syeda, K., Vinberg, M., Carvalho, A. F., Mansur, R. B., Maruschak, N., & Cha, D. S. (2015) · CNS Drugs · doi:10.1007/s40263-015-0263-x · Cited by 145 · cited 1×
“Among the symptoms most frequently reported, by patients and their relatives, special mention should be made of cognitive disorders, which include deficits in various domains: attention, executive functions, memory and processing speed.(9,10) These disorders often tend to persist even during remission of depressive sy…”
BackgroundUrethral injection therapy for urinary incontinence in women
Kirchin, V., Page, T., Keegan, P. E., Atiemo, K., Cody, J. D., McClinton, S., & Aluko, P. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003881.pub4 · Cited by 135
Severe depressive pseudodementia with and without dementia
McAllister, T. W., & Price, T. R. (1982) · American Journal of Psychiatry · doi:10.1176/ajp.139.5.626 · Cited by 119
Guilloux, J.-P., Mendez-David, I., Pehrson, A., Guiard, B. P., Repérant, C., Orvoën, S., Gardier, A. M., Hen, R., Ebert, B., Miller, S., et al. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.05.014 · Cited by 115
Pseudo-dementia: A neuropsychological review
Prakash, R., Kang, H., Zhao, F., You, L., Giorgetta, C., Venkatesh, D., & Sarkhel, S. (2014) · Annals of Indian Academy of Neurology · doi:10.4103/0972-2327.132613 · Cited by 112
Long-term outcome of depressive pseudodementia in the elderly
Fonseca, J. A. S., Lee, L., & Walker, Z. (2006) · Journal of Affective Disorders · doi:10.1016/j.jad.2006.11.004 · Cited by 111
Saragoussi, D., Christensen, M. C., Hammer-Helmich, L., Rive, B., Touya, M., & Haro, J. M. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s159276 · Cited by 110
Pseudodementia: Facts and Figures
Bulbena, A., & Berrios, G. E. (1986) · British Journal of Psychiatry · doi:10.1192/bjp.148.1.87 · Cited by 104
Wallace, A., Pehrson, A. L., Sánchez, C., & Morilak, D. A. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145714000571 · Cited by 97
Jensen, J. B., du Jardin, K. G., Song, D., Budac, D., Smagin, G., Sanchez, C., & Pehrson, A. L. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.10.011 · Cited by 96
Vortioxetine: A Review in Cognitive Dysfunction in Depression
Frampton, J. E. (2016) · Drugs · doi:10.1007/s40265-016-0655-3 · Cited by 90 · cited 1×
“In both these studies, vortioxetine was found to improve cognitive performances.(54) In three large randomized controlled studies in adults with recurrent”
ResultLu, Y., Ho, C. S., McIntyre, R. S., Wang, W., & Ho, R. C. (2018) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2018.06.007 · Cited by 90
Molecular, Functional, and Structural Imaging of Major Depressive Disorder
Zhang, K., Zhu, Y., Zhu, Y., Wu, S., Liu, H., Zhang, W., Xu, C., Zhang, H., Hayashi, T., & Tian, M. (2016) · Neuroscience Bulletin · doi:10.1007/s12264-016-0030-0 · Cited by 88
Hvenegaard, M. G., Bang‐Andersen, B., Pedersen, H., Jørgensen, M., Püschl, A., & Dalgaard, L. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.112.044610 · Cited by 86
Cognition in major depressive disorder: a ‘Systemically Important Functional Index’ (SIFI)
McIntyre, R. S., & Lee, Y. (2016) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000221 · Cited by 85
Pharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder
Alvarez, E., Artigas, F., & Perez, V. (2014) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s41387 · Cited by 84
Sonnenberg, C., Deeg, D. J. H., Comijs, H. C., van Tilburg, W., & Beekman, A. T. F. (2008) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.03.009 · Cited by 81
Depression and dementia: the multi-faceted relationship
Mahendra, B. (1985) · Psychological Medicine · doi:10.1017/s0033291700023503 · Cited by 79
Stenkrona, P., Halldin, C., & Lundberg, J. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.01.002 · Cited by 78
Miskowiak, K. W., Ott, C. V., Petersen, J. Z., & Kessing, L. V. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.09.641 · Cited by 77
Stahl, S. M. (2015) · CNS Spectrums · doi:10.1017/s1092852915000139 · Cited by 77
The Clinical Pharmacokinetics of Lu AA 21004 and its Major Metabolite in Healthy Young Volunteers
Areberg, J., Søgaard, B., & Højer, A. (2012) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2012.00886.x · Cited by 69 · cited 1×
“Studies have shown that vortioxetine possesses a linear pharmacokinetic profile.(38) Administered orally, it has a bioavailability of approximately 75%, irrespective of food intake.”
BackgroundAreberg, J., Luntang‐Jensen, M., Søgaard, B., & Nilausen, D. Ø. (2012) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2011.00810.x · Cited by 68
Bétry, C., Pehrson, A. L., Etiévant, A., Ebert, B., Sánchez, C., & Haddjeri, N. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712001058 · Cited by 62
Citrome, L. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.02.042 · Cited by 61
Assié, M., Lomenech, H., Ravailhe, V, Faucillon, V, & Newman‐Tancredi, A. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706859 · Cited by 61
Bétry, C., Etiévant, A., Pehrson, A., Sánchez, C., & Haddjeri, N. (2015) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2014.12.002 · Cited by 59
Vortioxetine for depression in adults
Koesters, M., Ostuzzi, G., Guaiana, G., Breilmann, J., & Barbui, C. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011520.pub2 · Cited by 56
Freeman, M. P., Cheng, L. J., Moustafa, D., Davies, A. C., Sosinsky, A. Z., Wang, B. H., Petrillo, L. F., Hogan, C. S., & Cohen, L. S. (2017) · Annals of Clinical Psychiatry · doi:10.1177/104012371702900407 · Cited by 54
Huang, M., Lu, S., Yu, L., Li, L., Zhang, P., Hu, J., Zhou, W., Hu, S., Wei, N., Huang, J., et al. (2017) · BMC Psychiatry · doi:10.1186/s12888-016-1190-1 · Cited by 46
Alzheimer's Disease and Other Dementias (Including Pseudodementias)
Lovestone, S. (2009) · doi:10.1002/9781444316803.ch9 · Cited by 45
Westrich, L., Haddjeri, N., Dkhissi-Benyahya, O., & Sánchez, C. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.10.015 · Cited by 40
de Girolamo, G., Polidori, G., Morosini, P., Mazzi, F., Serra, G., Scarpino, Reda, R., Visonà, G., Falsirollo, F., & Rossi, A. (2005) · PubMed · Cited by 38
Chen, F., du Jardin, K. G., Waller, J. A., Sanchez, C., Nyengaard, J. R., & Wegener, G. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.12.018 · Cited by 37
Depression in the Italian community: epidemiology and socio-economic implications
Battaglia, A., Dubini, A., Mannheimer, R., & Pancheri, P. (2004) · International Clinical Psychopharmacology · doi:10.1097/00004850-200405000-00003 · Cited by 37
Heser, K., for the AgeCoDe Study Group, Bleckwenn, M., Wiese, B., Mamone, S., Riedel-Heller, S. G., Stein, J., Lühmann, D., Posselt, T., Fuchs, Â., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160209 · Cited by 34
Şahin, Ş., Okluoglu, T., Çınar, N., Bozdemir, M., Çubuk, R., & Karşıdağ, S. (2017) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000477759 · Cited by 32
Vortioxetine for the Treatment of Depression
Pearce, E. F., & Murphy, J. A. (2014) · Annals of Pharmacotherapy · doi:10.1177/1060028014528305 · Cited by 29
Waller, J. A., Chen, F., & Sánchez, C. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.12.012 · Cited by 25
Using Measurement Strategies to Identify and Monitor Residual Symptoms
McIntyre, R. S. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12084su1c.03 · Cited by 25
A Commentary on the Proposed DSM Revision Regarding the Classification of Cognitive Disorders
Rabins, P. V., & Lyketsos, C. G. (2010) · American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e3182051ac7 · Cited by 23
Mahableshwarkar, A. R., Zajecka, J., Jacobson, W., Chen, Y., & Keefe, R. S. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2016.181 · Cited by 15
Effects of ondansetron on short-term memory retrieval in mice.
Roychoudhury, M., & Kulkarni, S. K. (1997) · PubMed · Cited by 13
Vortioxetine Improves Context Discrimination in Mice Through a Neurogenesis Independent Mechanism
Felice, D., Guilloux, J., Pehrson, A. L., Li, Y., Mendez‐David, I., Gardier, A. M., Sánchez, C., & David, D. J. P. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00204 · Cited by 12
Italian psychiatrists’ perception on cognitive symptoms in major depressive disorder
Albert, U., Brugnoli, R., Caraci, F., Dell’Osso, B. M., Sciascio, G. D., Tortorella, A. A. V., Vampini, C., Cataldo, N., & Pegoraro, V. (2015) · International Journal of Psychiatry in Clinical Practice · doi:10.3109/13651501.2015.1093147 · Cited by 12
Vortioxetina nel trattamento della depressione maggiore
de Bartolomeis, A., Fagiolini, A. M., & Maina, G. (2016) · Rivista di psichiatria · doi:10.1708/2596.26720 · Cited by 12
Cited by
Tartt, A. N., Mariani, M. B., Hen, R., Mann, J. J., & Boldrini, M. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01520-y · Cited by 408
Protective role of IGF-1 and GLP-1 signaling activation in neurological dysfunctions
Bhalla, S., Mehan, S., Khan, A., & Rehman, M. U. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104896 · Cited by 108
The association between allostatic load and brain: A systematic review
Lenart-Bugla, M., Szcześniak, D., Bugla, B., Kowalski, K., Niwa, S., Rymaszewska, J., & Misiak, B. (2022) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2022.105917 · Cited by 61
Suzuki, A., Hara, H., & Kimura, H. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109308 · Cited by 46
Huang, I.-C., Chang, T.-S., Chen, C., & Sung, J.-Y. (2022) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyac054 · Cited by 41
“Overall, the studies supported vortioxetine as the first antidepressant drug to demonstrate proven efficacy in improving the cognitive symptoms of depression (Perini et al., 2019).”
Result
Metadata
- Authors
- Perini, G., Cotta Ramusino, M., Sinforiani, E., Bernini, S., Petrachi, R., & Costa, A.
- Affiliations
- University of Pavia (IT)
- Fondazione Istituto Neurologico Nazionale Casimiro Mondino (IT)
- Corresponding author
- Costa, Alfredo
- Venue
- Neuropsychiatric Disease and Treatment
- Publisher
- Informa UK Limited
- Published
- 2019-05
- Volume
- Volume 15
- Pages
- 1249-1258
- ISSN
- 1176-6328 (ISSN-L)
- 1178-2021
- PMC
- PMC6520478
- OpenAlex
- W2943996957
- Cited by
- 384
- References
- 73
- Citations by year
- 2026: 42 · 2025: 56 · 2024: 65 · 2023: 80 · 2022: 67 · 2021: 51 · 2020: 21 · 2019: 2
- FWCI
- 22.01
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Neuropsychiatric Disease and Treatment (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- H. Lundbeck A/S
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Keywords
- cognitive impairment in depression, pseudodementia, multimodal antidepressant, vortioxetine, pharmacodynamics, pharmacokinetics, mechanism of action, depression recurrence, quality of life, antidepressant treatment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
